Weekly Digest – February 2025 Weekly Digest – February 2025 14 Feb 2025: 1st Trop-2 ADC Trodelvy expands indication to metastatic HR+/HER2- breast cancer Trodelvy (Sacituzumab govitecan) received expanded approval in Korea to treat metastatic HR+/HER2- breast cancer resistant to […]
Weekly Digest – February 2025 Weekly Digest – February 2025 31 Jan 2025: Datopotamab deruxtecan recommended for approval in the EU by CHMP for patients with previously treated metastatic HR-positive, HER2-negative breast cancer Datopotamab deruxtecan has been recommended for approval […]
Weekly Digest – February 2025 Weekly Digest – February 2025 31 Jan 2025: Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU The FDA approved a label expansion for […]
Weekly Digest – February 2025 Weekly Digest – February 2025 04 Feb 2025: Pyxis Oncology initiates new PYX-201 combination trial and initiates cohort expansions of ongoing monotherapy trial Pyxis Oncology announced progress in its clinical program for PYX-201, an ADC […]
Weekly Digest – February 2025 Weekly Digest – February 2025 04 Feb 2025: Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates Pfizer has discontinued the development of its B7-H4-directed ADC, B7H4V, resulting in a $1 billion […]
Weekly Digest – February 2025 Weekly Digest – February 2025 06 Feb 2025: Merck announces phase 3 waveLINE-010 trial initiation evaluating Zilovertamab Vedotin, an investigational antibody-drug conjugate, for the treatment of patients with previously untreated diffuse large B-cell lymphoma Merck […]
Weekly Digest – February 2025 Weekly Digest – February 2025 06 Feb 2025: Anti-HER2 bispecific ADC JSKN003 received approval to initiate a phase 3 clinical study for the treatment of HER2-positive breast cancer Alphamab oncology and CSPC pharmaceutical received NMPA […]
